Methotrexate vs cyclosporin a as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from hla-identical siblings: a single-center analysis in japan

SUMMARY: The efficacy of methotrexate (MTX) as a single graft-versus-host disease (GVHD) prophylaxis agent was compared to that of cyclosporin A (CSA) in 62 pediatric patients (median age: 8

years) with hematological malignancies who had undergone bone marrow transplantation (BMT) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977. In all, 30 patients

received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then once a week until day +100. A total of 32 patients

were treated with CSA, which was given intravenously in the early stages and orally thereafter until day +100, and then gradually tapered and stopped 6 months after BMT. There were no

differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II–IV) and chronic GVHD were 29.6 _vs_ 40.6% (_P_=0.294) and 19

_vs_ 20% (MTX _vs_ CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese

pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients. Access through your

institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print

issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT

BEING VIEWED BY OTHERS COMPARISON OF MYCOPHENOLATE MOFETIL AND CALCINEURIN INHIBITOR VERSUS CALCINEURIN INHIBITOR-BASED GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS FOR MATCHED UNRELATED DONOR

TRANSPLANT IN ACUTE MYELOID LEUKEMIA. A STUDY FROM THE ALWP OF THE EBMT Article 28 November 2020 POST-TRANSPLANT CYCLOPHOSPHAMIDE, CALCINEURIN INHIBITOR, AND MYCOPHENOLATE MOFETIL COMPARED

TO ANTI-THYMOCYTE GLOBULIN, CALCINEURIN INHIBITOR, AND METHOTREXATE COMBINATIONS AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS POST ALLOGENEIC STEM CELL TRANSPLANTATION FROM SIBLING AND UNRELATED

DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION Article 13 April 2024

LOW-DOSE ANTITHYMOCYTE GLOBULIN PLUS LOW-DOSE POSTTRANSPLANT CYCLOPHOSPHAMIDE COMBINED WITH CYCLOSPORINE AND MYCOPHENOLATE MOFETIL FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER

HLA-MATCHED UNRELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Article Open access 25 May 2021 REFERENCES * Goker H, Haznedaroglue IC, Chao NJ . Acute graft-versus-host disease:

Pathophysiology and management. _Exp Hematol_ 2001; 29: 259–277. Article  CAS  PubMed  Google Scholar  * Nash RA, Antin JH, Karanes C _et al_. Phase 3 study comparing methotrexate and

tacrolimus with methotrexate and cyclo-sporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. _Blood_ 2000; 96: 2062–2068. CAS  PubMed

  Google Scholar  * Hiraoka A, Ohashi Y, Okamoto S _et al_. Phase II study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone

marrow transplantation. _Bone Marrow Transplant_ 2001; 28: 181–185. Article  CAS  PubMed  Google Scholar  * Ringden O, Horowitz MM, Sondel P _et al_. Methotrexate, cyclosporine, or both to

prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. _Blood_ 1993; 81: 1094–1101. CAS  PubMed  Google Scholar  * Locatelli F, Zecca M,

Rondelli R _et al_. Graft versus host disease prophylaxis with low-dose cyclosporin-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow

transplantation: results of a randomized trial. _Blood_ 2000; 95: 1572–1579. CAS  PubMed  Google Scholar  * Storb R, Epstein RB, Graham TC _et al_. Methotrexate regimens for control of

graft-versus host disease in dogs with allogeneic marrow grafts. _Transplantation_ 1970; 9: 240–246. Article  CAS  PubMed  Google Scholar  * Deeg HJ, Storb R, Thomas ED _et al_. Cyclosporine

as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. _Blood_ 1985; 65: 1325–1334. CAS  PubMed

  Google Scholar  * Glucksberg H, Storb R, Fefer A _et al_. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors.

_Transplantation_ 1974; 18: 295–304. Article  CAS  PubMed  Google Scholar  * Shulman HM, Sullivan KM, Weiden PL _et al_. Chronic graft-versus-host disease syndrome in man. A long-term

clinicopathologic study of 20 Seattle patients. _Am J Med_ 1980; 69: 204–217. Article  CAS  PubMed  Google Scholar  * Thomas E, Storb R, Clift RA _et al_. Bone marrow transplantation. _N

Engl J Med_ 1975; 292: 832–843. Article  CAS  PubMed  Google Scholar  * Deeg HJ, Storb R . Graft-versus-host disease: pathophysio-logical and clinical aspects. _Ann Rev Med_ 1984; 35: 11–24.

Article  CAS  PubMed  Google Scholar  * Maruya E, Saji H, Seki S _et al_. Evidence that CD31, CD49b, and Cd62L are immunodominant minor histocompatibility antigens in HLA-identical sibling

bone marrow transplants. _Blood_ 1998; 92: 2169–2176. CAS  PubMed  Google Scholar  * Storb R, Deeg HJ, Fisher L _et al_. Cyclosporin _vs_ methotrexate for graft-versus-host disease

prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. _Blood_ 1988; 71: 293–298. CAS  PubMed  Google Scholar  * Teshima T, Ferrara JL .

Understanding the allo response: New approaches to graft-versus-host disease prevention. _Semin Hematol_ 2002; 39: 12–22. Article  Google Scholar  * Storb R, Deeg HJ, Whitehead J _et al_.

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. _N Engl J Med_ 1986; 314:

729–735. Article  CAS  PubMed  Google Scholar  * Ratanatharathorn V, Nash RA, Pzepiorka D _et al_. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate

and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. _Blood_ 1998; 92: 2303–2314. CAS  PubMed  Google Scholar  * Yanik G,

Levine JE, Ratanatharathorn V _et al_. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplant-ation. _Bone Marrow

Transplant_ 2000; 26: 161–167. Article  CAS  PubMed  Google Scholar  * Storb HJ, Deeg ED, Thomas _et al_. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of

cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. _Blood_ 1985; 66: 698–702. CAS  PubMed  Google Scholar  * Peter C, Minkov M, Gadner H _et al_. Statement of

current majority practice in graft-versus-host disease prophylaxis and treatment in children. _Bone Marrow Transplant_ 2000; 26: 405–411. Article  Google Scholar  Download references

ACKNOWLEDGEMENTS We are grateful to the nursing staff at National Kyushu Cancer Center during the study period. We thank the resident doctors for their contribution in caring for the

transplanted patients. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan Y Koga, Y Nagatoshi, Y Kawano & J Okamura *

Department of Pediatrics, University of Kagoshima, Kagoshima, Japan Y Kawano Authors * Y Koga View author publications You can also search for this author inPubMed Google Scholar * Y

Nagatoshi View author publications You can also search for this author inPubMed Google Scholar * Y Kawano View author publications You can also search for this author inPubMed Google Scholar

* J Okamura View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Koga,

Y., Nagatoshi, Y., Kawano, Y. _et al._ Methotrexate _vs_ Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies

undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. _Bone Marrow Transplant_ 32, 171–176 (2003).

https://doi.org/10.1038/sj.bmt.1704051 Download citation * Received: 11 June 2002 * Accepted: 06 November 2002 * Published: 02 July 2003 * Issue Date: 01 July 2003 * DOI:

https://doi.org/10.1038/sj.bmt.1704051 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * methotrexate * cyclosporin * GVHD prophylaxis *

pediatric patients * Japanese